Y-mAbs Therapeutics (YMAB, Financial) recently shared that the National Comprehensive Cancer Network (NCCN) has endorsed naxitamab-gqgk. This approval is part of the NCCN Clinical Practice Guidelines in Oncology, marking it as a Category 2A treatment option for patients with high-risk neuroblastoma.
The inclusion of naxitamab-gqgk in these guidelines underscores its significance as a preferred anti-GD2 therapy for healthcare professionals dealing with relapsed or refractory cases of high-risk neuroblastoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.